Abstract Background Combinations of PD-1/PD-L1 immune checkpoint inhibitors (ICI) with
VEGFR-TKIs as first-line therapy significantly improve outcomes of metastatic renal cell …

Introduction We have experienced several paradigm shifts and substantial changes in the
treatment of metastatic renal cell carcinoma (mRCC) over the last two decades. Combination …

Abstract Context Immune checkpoint inhibitors (ICIs) have reported unprecedented results in
the treatment of metastatic renal cell carcinoma (mRCC) patients, as monotherapy or in …

Background Although immune checkpoint inhibitors (ICIs) combined with vascular
endothelial growth factor receptor (VEGFR)-targeted therapy and sunitinib monotherapy …

The recent approval of immune checkpoint inhibitor (ICI)-based combinations has redefined
the first-line standard of care of metastatic renal cell carcinoma (mRCC) patients. Although …

BACKGROUND The outcome of patients who progress on front-line immune-based
combination regimens (IC) including immune checkpoint inhibitors (CPI) and receive …

Simple Summary We evaluated the efficacy and safety of immune checkpoint inhibitors
(ICIs) and tyrosine kinase inhibitors (TKI)(ICI+ TKI) in 51 patients with advanced or …

Introduction Immune checkpoint inhibitor (ICI) combination therapy has changed the
treatment landscape for metastatic renal cell carcinoma (mRCC). However, little evidence …

In the past 10 years, immune checkpoint inhibitors (ICIs) have been used to manage
metastatic renal cell carcinoma (mRCC). Different combinations of ICIs and tyrosine kinase …

Background Immune checkpoint inhibitor/tyrosine kinase inhibitor (ICI/TKI) combinations are
a new standard of care for the initial treatment of metastatic renal cell carcinoma (mRCC) …